These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 34159737

  • 1. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y, Inomata S, Yamaguchi H, Mine H, Takagi H, Watanabe M, Ozaki Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Hasegawa T, Shio Y, Suzuki H.
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [Abstract] [Full Text] [Related]

  • 2. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES, Barlesi F, Mok T, Ahn MJ, Shen J, Zhang P, Ou SI.
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [Abstract] [Full Text] [Related]

  • 3. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ, Dai XY, Qiu Y, Liu XN, Zeng CM, Xu XY, Chen YD, Zhu H, He QJ, Gai RH, Ma SL, Chen XQ, Yang B.
    Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931
    [Abstract] [Full Text] [Related]

  • 4. Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.
    Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y.
    Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer.
    Yoshida H, Kim YH, Ozasa H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Yamamoto T, Ajimizu H, Hirai T.
    In Vivo; 2018 Nov; 32(6):1587-1590. PubMed ID: 30348720
    [Abstract] [Full Text] [Related]

  • 6. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
    Kawauchi D, Takahashi M, Satomi K, Yamamuro S, Kobayashi T, Uchida E, Honda-Kitahara M, Narita Y, Iwadate Y, Ichimura K, Tomiyama A.
    Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771
    [Abstract] [Full Text] [Related]

  • 7. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y, Yamamoto N, Masters ET, Kikkawa H, Mardekian J, Wiltshire R, Togo K, Ohe Y.
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
    Luo X, Zhou Z, Zeng X, Peng L, Liu Q.
    Front Public Health; 2022 Jul; 10():985834. PubMed ID: 36211665
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Reckamp K, Lin HM, Huang J, Proskorovsky I, Reichmann W, Krotneva S, Kerstein D, Huang H, Lee J.
    Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
    [Abstract] [Full Text] [Related]

  • 10. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT, Chiang CL, Hung JY, Lee MH, Su WC, Wu SY, Wei YF, Lee KY, Tseng YH, Su J, Chung HP, Lin CB, Ku WH, Chiang TS, Chiu CH, Shih JY.
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [Abstract] [Full Text] [Related]

  • 11. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.
    Koshikawa K, Terada J, Abe M, Iwasawa S, Sakayori M, Yoshioka K, Hirasawa Y, Kasai H, Kawasaki Y, Tsushima K, Tatsumi K.
    Thorac Cancer; 2020 Jun; 11(6):1495-1502. PubMed ID: 32237210
    [Abstract] [Full Text] [Related]

  • 12. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B.
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [Abstract] [Full Text] [Related]

  • 13. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT.
    Clin Cancer Res; 2014 Nov 15; 20(22):5686-96. PubMed ID: 25228534
    [Abstract] [Full Text] [Related]

  • 14. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
    Dong X, Fernandez-Salas E, Li E, Wang S.
    Neoplasia; 2016 Mar 15; 18(3):162-71. PubMed ID: 26992917
    [Abstract] [Full Text] [Related]

  • 15. Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Metro G, Tazza M, Matocci R, Chiari R, Crinò L.
    Lung Cancer; 2017 Apr 15; 106():58-66. PubMed ID: 28285695
    [Abstract] [Full Text] [Related]

  • 16. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
    Wilkinson S, Gupta A, Scheuer N, Mackay E, Arora P, Thorlund K, Wasiak R, Ray J, Ramagopalan S, Subbiah V.
    JAMA Netw Open; 2021 Oct 01; 4(10):e2126306. PubMed ID: 34618040
    [Abstract] [Full Text] [Related]

  • 17. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS, Tung PH, Huang AC, Wang CC, Chang JW, Liu CY, Chung FT, Fang YF, Guo YK, Yang CT.
    BMC Cancer; 2021 Mar 24; 21(1):309. PubMed ID: 33761908
    [Abstract] [Full Text] [Related]

  • 18. Analysis of the resistance profile of real-world alectinib first-line therapy in patients with ALK rearrangement-positive advanced non-small cell lung cancer using organoid technology in one case of lung cancer.
    Xie Y, Zhang Y, Wu Y, Xie X, Lin X, Tang Q, Zhou C, Xie Z.
    J Thorac Dis; 2024 Jun 30; 16(6):3854-3863. PubMed ID: 38983150
    [Abstract] [Full Text] [Related]

  • 19. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
    Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S.
    J Thorac Oncol; 2020 May 30; 15(5):752-765. PubMed ID: 31972351
    [Abstract] [Full Text] [Related]

  • 20. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
    Tomasini P, Egea J, Souquet-Bressand M, Greillier L, Barlesi F.
    Ther Adv Respir Dis; 2019 May 30; 13():1753466619831906. PubMed ID: 30786826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.